William E. Steinkrauss
Plus aucun poste en cours
Fortune : 45 328 $ au 31/03/2024
Profil
William E.
Steinkrauss worked as a Director-Technical Accounting & Reporting at OvaScience, Inc. from 2015 to 2016.
Prior to that, he was a Senior Manager-Technical Accounting at Cubist Pharmaceuticals LLC from 2012 to 2015.
Currently, he is the Chief Financial & Administrative Officer at Curis, Inc. starting from 2016.
Steinkrauss completed his undergraduate and graduate degrees from Boston College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CURIS, INC.
0,07% | 31/07/2023 | 4 170 ( 0,07% ) | 45 328 $ | 31/03/2024 |
Anciens postes connus de William E. Steinkrauss
| Sociétés | Poste | Fin |
|---|---|---|
| CURIS, INC. | Director of Finance/CFO | 05/08/2022 |
OvaScience, Inc.
 OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/08/2016 |
| CUBIST PHARMACEUTICALS INC | Corporate Officer/Principal | 01/05/2015 |
Formation de William E. Steinkrauss
| Boston College | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CURIS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA. | Health Technology |
